RU2561837C2 - Method of treating patients with type 2 diabetes mellitus - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: method starts with a two-staged bioresonance exposure generated by the DETA-Professional apparatus. The first stage represents a baseline therapy and involves 3-5 procedures of the total body exposure, which is ensured by connecting an input electrode upon the measurement procedure to the patient's limb having the highest electromagnetic potential, whereas an output electrode is supposed to be connected to the limb with the lowest electromagnetic potential. Carrying out the exposure observes the following parameters: the first phase is filter-free (FF) at amplification (A) of 20 for 3-4 minutes. The second phase represents the low-frequency (LF) exposure at 1-1,000 Hz, amplification (A) of 16 for 3-4 minutes. The third phase represents the high-frequency (HF) exposure at 1,000-10,000 Hz, amplification (A) of 12 for 3-4 minutes. The exposure is daily. The second stage involves a target therapy consisting of 5-7 procedures of 30-40 minutes each. The exposure covers the entire anatomy of the pancreas and its acupuncture points RP1, RP2, RP3, RP4, TR-1c from the right and left at low frequencies (LF) ranging from 1 to 1,000 Hz, amplification A of 14-35. That is immediately followed by yellow light exposure at a wavelength of 590 nm, intensity of 3 kJ, red light exposure at a wavelength of 650 nm, intensity of 3-4 kJ, and green light exposure at a wavelength of 520 nm, intensity of 4 kJ. At that used is the quasicontinuous radiation mode at a frequency of 1,000 or 80 Hz and the modulated mode at 1,000 or 80 Hz at a modulation of 2 Hz. Each light exposure lasts for no more than 5 minutes and covers a skin projection of the pancreas in the distant mode and the point TR-1 in the contact mode by means of the DETA-Professional apparatus and a phototherapy terminal. Similarly to the first stage, the exposure is daily.

EFFECT: reducing the length of treatment in the given category of patients as a result of lower blood glucose as late as the early stage of treatment with keeping the permanent result in the remote period by a certain stage-by-stage approach of the bioresonance exposure and radiation modes.

1 tbl, 3 ex

Description

The invention relates to medicine and is intended for the treatment of patients with type 2 diabetes mellitus (DM).

Type 2 diabetes is an acute social problem related to the priorities of national health systems in almost all countries of the world. The drama and urgency of the problem are determined by the widespread prevalence of this endocrine disease, high mortality and early disability of patients. According to the International Federation of Diabetes, the number of patients with type 2 diabetes in the world in 2010 amounted to 285 million people (6.6% of the population). According to forecasts, by 2030, the prevalence of the disease will increase to 7.8%. [Gonchar V.N., Bashnina EB, Vorokhobina N.V. // Type 2 diabetes mellitus in young people: etiology, pathogenesis, diagnosis and treatment. - Tutorial. - SPbMAPO. 2012 .-- 22 p. - S. 4].

Therefore, type 2 diabetes poses a real threat to the health and quality of life of the world's population, being one of the most common chronic diseases. Vascular complications of type 2 diabetes (micro- and macroangiopathy), such as nephropathy, retinopathy, damage to the main vessels of the heart, brain, lower extremities, are chained to a wheelchair annually and kill millions of people suffering from this disease. [Dedov I.I., Melnichenko G.A. Endocrinology. National leadership / M .: GEOTAR-Media, 2008. - S. 352-463]. Such a wide range of complications developing in type 2 diabetes explains the high interest in the problem and the participation in the treatment of these patients, not only endocrinologists, diabetologists, but specialists from almost all medical fields.

In recent years, a real breakthrough has been made in providing quality medical care to patients with type 2 diabetes. At present, the best of the existing insulins, the genetically engineered human insulins and their analogues, have been introduced into everyday practice. Modern tableted medicines have appeared to eliminate the main causes leading to the development of type 2 diabetes, new secretagogues, insulin sensitizers, the latest means of insulin administration, as well as a monitoring system for the quality of treatment and control of type 2 diabetes [I. Dedov. 2006; Schwartz W., 2008; Nathan D.M., 2009]. However, the problem of diabetes is not resolved. More: 50-70% of patients with type 2 diabetes in all countries of the world are in a state of unsatisfactory compensation of carbon metabolism, which inevitably leads to the development of fatal and disabling vascular complications [G. Melnichenko // Practical medicine. 2009. - 197 S.].

At present, along with the medical treatment of type 2 diabetes, many auxiliary methods are used, such as treatment, increased oxygen pressure, sorption detoxification methods, acupuncture and its various modifications, and spa treatment. Modern statistics indicate that reducing the incidence of type 2 diabetes can be achieved by modifying the lifestyle [Nedosugova T.V. / New approaches to the treatment of type 2 diabetes mellitus // Russian Medical Journal. 2006. - T. 14. - No. 13. - S. 2-5].

There are known physical methods of influencing pancreatic function in the treatment of type 2 diabetes, which include: laser therapy, ultrasound treatment, mm electromagnetic range electromagnetic therapy (EHF therapy).

In the treatment of type 2 diabetes, magnetic therapy was used with the MIT11 apparatus in the projection of the pancreas (pancreas), magnetotherapy was performed at a frequency of 10-50 mt, laser therapy with a wavelength (λ = 0.78 mm) of 10-100 mv. Duration of therapy 20-30 min. Course of 10-20 procedures. // Kholodova EA Clinical endocrinology: a Guide for doctors. - M.: Medical Information Agency LLC, 2011. - 704-706 p.

The disadvantage of this method of treatment is the lack of hypoglycemic effect and frequent remissions of hyperglycemia. As well as magnetic laser therapy is combined with antioxidant therapy, and in the described method of treatment it is absent.

The treatment of type 2 diabetes with ultrasound was performed with a frequency of 22-100 kHz, an amplitude of 5.2 μm and a modulation frequency of 1-10 Hz. The duration of therapy is 5-15 minutes. They also acted on acupuncture points (TA): J (XIV) 12, J (XIV) 6, E (III) 25 to stimulate bowel function. Ultrasound was applied daily, with a duration of 1-2 minutes at each acupuncture point, the vibration amplitude was 4 μm, and the frequency was 44 kHz. The procedures were carried out daily for 10-21 days [Turova EA, Tenyaeva EA, Golovach A.V. Physio- and balneotherapy of diabetes mellitus // Questions of balneology, physiotherapy and physiotherapy. - 1999. - No. 6. - C 43-48].

The disadvantage of this method is that exposure to a frequency of 22-100 kHz on the pancreas region leads to stress in the cells of the gland, which will be manifested by an increase in the mitotic effect. As is known, biophysical changes in cells occur at a more subtle level of oscillations from units of Hz to 1 KHz. Therefore, this method is not widespread in the physiotherapy of type 2 diabetes due to lack of effectiveness.

In the treatment of type 2 diabetes with mm-band electromagnetic radiation (EHF-therapy), they acted on the acupuncture points of the pancreas (Rp1, Rp2, Rp3, Rp4) in combination with the basic therapy of type 2 diabetes. The exposure to low-intensity electromagnetic radiation of the mm range was performed on acupuncture points (TA), in order to most stimulate the intestines and autonomic homeostasis. For EHF therapy, the MIT-LT-1 UHF device with a power of 2 mW was used. In quasi-noise mode (wavelength - 4.2-7.1 mm). For one session, 3 to 5 TAs were used. Each point was exposed for 5-10 minutes, the total duration of the session was 30 minutes. EHF treatments were performed daily, with a total of 15-20 procedures [Samosiuk I., Vladimirov O., Chukhraeva O., Maikovets V., Samosiuk N., Nalazek A., Zukow W. Journal of Health Sciences. 2011. T. 1. No. 4. C. 101-124].

The disadvantage of this method is the lack of immunostimulating action, and in the future, the possible acceleration of pancreatic degeneration due to the use of high frequencies of electromagnetic waves.

There is also a method of treating type 2 diabetes, which consists in magnetotherapy. By random sampling, all the examined were divided into three groups: in the 1st main (30 people) basic treatment was supplemented by a course of general magnetotherapy (OMT); in the second (30 people) - by local magnetotherapy on the lumbar segments of the spine (L2-L4) and lower extremities, in the 3rd group (comparison group), consisting of 18 people, hardware physiotherapy was not performed. OMT was carried out on an automated magneto-therapeutic unit Alma (OJSC ALMA, Biysk, Russia). A sinusoidal rotating magnetic field exposure program was applied with a maximum induction of 3.2 mT and a rotation frequency of 100 and 50 Hz, the duration of the procedure was 15 minutes, the course was 10 procedures conducted daily except Sunday. Local MT was performed on an ALIMP-1 apparatus with a magnetic field pulse frequency of 100 Hz and magnetic induction in the geometric center of a 5 mT solenoid inductor, the magnetic induction adjustment level was 30%, the procedure time was 20 minutes, every day except Sunday, the course consisted of 10 procedures. [Tunikovskaya O. V., Kareva N. P., Chernova N. N., Drobyshev V. A. Medicine and education in Siberia. 2009. No5. C 16].

The method has insufficient treatment effectiveness.

A known method for the treatment of type 2 diabetes by bioresonance exposure using the apparatus "DETA-Professional". "DETA-Professional" includes diagnostics according to R. Voll, diagnostics according to the method of X. Schimmel (vegetative resonance test) and treatment, bioresonance, electromagnetic and complex therapies, built-in electronic medical selector, software "EAVPRO" version 3.0 for Windows. [http://elis-deta.ru/DetaElis-prof.htm].

In the passport for the DETA-Professional device, diabetes is listed in the list of diseases recommended for treatment with this device [http://devitacenter.com/documents → Documents and descriptions → Device composed of electroacupunctural diagnostics, pharmacological testing, electroacupunctural, electromagnetic, guantum and bioresonance therapy units DETA-Professional, c. 22]. Unfortunately, the passport does not indicate a specific diabetes treatment. It is indicated that when you turn on the BRT mode using the "Power" button on the "BRT" panel, the doctor selects the rules for using this method using the guidelines for using bioresonance therapy. There are no guidelines for using the "DETA-Professional" device. However, the basic principle of operation of devices for bioresonance therapy "DETA", produced by the scientific and production enterprise "Ellis", is the same. The method of treatment using bioresonance therapy is described in the guidelines for the medical device for bioresonance therapy "DETA-BRT". [Likharev V.V. Guidelines for the medical device for bioresonance therapy "DETA-BRT" NPP "Ellis", 2006 - 102 s]. Treatment includes 2 stages: basic therapy and targeted therapy. At the first stage, the stage of basic therapy, the inlet and outlet electrodes are connected to extra-meridian points on the thumbs and toes. [Likharev V.V. Guidelines for the medical device for bioresonance therapy "DETA-BRT" NPP "Ellis", 2006 - S. 28], that is, connect the input electrode to the limb of a person with the highest electromagnetic potential, and the output to the limb of a person with the lowest electromagnetic potential, and carry out a bioresonant effect on the whole body daily. The following parameters are used for this: Therapy: "Interruption on." mode: (BF) without filter, inverter: "Invert on." Amplification A - 30, exposure time (Time TI): 6 minutes [Methodical recommendations for the medical device for bioresonance therapy "DETA-BRT", Likharev V.V. NPP Ellis, 2006, 102 pp. - S. 86].

At the second stage, the stage of targeted therapy, it is recommended to conduct an effect on TAs that are clearly associated with this disease [Methodical recommendations for the medical device for bioresonance therapy "DETA-BRT" Likharev V.V. NPP Ellis, 2006, 102 pp. - S. 31]. Such TA in type 2 diabetes mellitus are: Rp1, Rp2, Rp3, Rp4, TR-1c, located in the anatomical region of the pancreas on the right and left.

TA - Rp1, Rp2, Rp3, Rp4 are points of exocrine function, and TR-TR-1c - endocrine. In this case, the following mode is used: Therapy: "Interruption on." Filter: RF 1000 Hz. Inverter: Invert On Gain A is 15. Exposure Time (Time TI): 4, increasing to 8 minutes. [Guidelines for the medical device for bioresonance therapy "DETA-BRT", Likharev V.V. NPP Ellis, 2006, 102 pp. - C 94].

According to its own data, the above analogue has insufficient treatment efficiency.

As a prototype for the closest technical essence, we have chosen a method for the prevention and treatment of patients with type 2 diabetes mellitus, which consists in exposure to a blue light spectrum as part of complex therapy. The method is safe, simple to implement, reduces the drug load on the patient (RU 2463089 10.10.10.2012).

The claims of this invention do not indicate the duration of the course of treatment. In a single clinical example for a method for the treatment of type 2 diabetes mellitus, it is indicated that the patient underwent 14 sessions of phototherapy, after which the medication was canceled, but phototherapy was continued. "Subsequent procedures contribute to the maintenance of blood glucose of not more than 6.0 mmol / L." It is further noted that after 60 sessions (daily procedures in the morning and evening), the patient's weight decreased by 5.9 kg. Thus, we can conclude that at least 60 sessions were conducted, taking into account the fact that the sessions were carried out in the morning and in the evening, the treatment was carried out for at least 30 days.

In the same clinical example, it is stated: "Before treatment in this patient, the blood glucose in the morning on an empty stomach was 11.0 mmol / L. Subsequent procedures contribute to maintaining glucose in the blood no more than 6.0 mmol / L." This refers to the continuation of the procedures after 14, that is, a decrease in glucose in the blood of patients was observed after more than 14 procedures.

Thus, it can be argued about the duration of treatment by the method chosen by us as a prototype. The description also does not contain information about the glucose content in the blood of patients in the long-term period, for example, 6 months after treatment, that is, it is not known whether a stable treatment result remains in the long-term period.

The technical result of the invention is to shorten the treatment of patients with type 2 diabetes mellitus, reduce the glucose content in the blood of patients at an earlier stage of treatment, as well as maintain a stable treatment result in the long term.

The technical result of the invention is achieved in that a method of treating patients with type 2 diabetes mellitus consists in bioresonance exposure using the apparatus "DETA-Professional", which is carried out in 2 stages. The first stage, the stage of basic therapy, includes 3-5 procedures for influencing the entire body, for which, after the measurement, the incoming electrode is connected to the limb of the patient with the highest electromagnetic potential, and the output to the limb with the lowest electromagnetic potential. In this case, the following parameters are applied: in the first phase they act without a filter (BF), with a gain height (A) equal to 20, duration 3-4 minutes, in the second phase low frequencies (LF) 1-1000 Hz, with a gain height (A ), equal to 16, lasting 3-4 minutes, in the third phase they are exposed to high frequencies (HF) of 1000-10000 Hz, with a gain height (A) of 12, lasting 3-4 minutes. Exposure is carried out daily for 1 procedure. The second stage, the stage of targeted therapy, includes 5-7 procedures for 30-40 minutes each, while affecting the entire anatomical region of the pancreas and its acupuncture points RP1, RP2, RP3, RP4, TR-1c on the right and left, use low frequencies (LF) from 1 to 1000 Hz, with a gain height A equal to 14-35. Immediately after this, they are affected by yellow light emission - a wavelength of 590 nm, a power of 3 kJ, red light emission of a wavelength of 650 nm, a strength of 3-4 kJ and green light emission of a wavelength of 520 nm, a strength of 4 kJ, while using a quasi-continuous radiation mode frequency - 1000 or 80 Hz and modulated - 1000 or 80 Hz with a modulation of 2 Hz. Each light is exposed for no more than 5 minutes to the area of the cutaneous projection of the pancreas distantly and to the point TR-1 using the "DETA-Professional" apparatus using the terminal for light therapy. The impact, as in the first stage, is carried out daily by 1 procedure.

The method is as follows:

The course of treatment is 8-12 procedures. Treatment consists of two stages, basic and target therapy, while using the apparatus "DETA-Professional". First of all, biologically active measuring points (TI) of the functional state of the pancreas (pancreas) are evaluated.

First step. It consists of 3-5 procedures for 9-12 minutes of basic therapy, while affecting the entire body in order to optimize and improve the function of the main vital organs. Daily spend on 1 procedure.

In this case, use manual and foot roller, plate and point electrodes.

A quadrant measurement is carried out (hand-hand, hand-foot, foot-foot), based on these measurements, the input electrode is connected to a human limb with the highest electromagnetic potential, and the output electrode is connected to a human limb with the lowest electromagnetic potential. The following BRT frequencies are used:

1. Phase: BF (without filter), A_ (gain) = 20, duration - 3-4 minutes.

2. Phase: LF (low frequencies) 1-1000 Hz, A_ (gain) = 16, duration - 3-4 minutes.

3. Phase: HF (high frequencies) 1000-10000 Hz, A_ (gain) = 12, duration - 3-4 minutes.

The second stage, the stage of targeted therapy, includes daily administration of 1 BRT procedure lasting 30-40 minutes, followed by light therapy with yellow, red and green light sequentially for 10-15 for 5-7 days. Bioresonance effect is carried out on the entire anatomical region of the pancreas, and immediately after that - on its acupuncture points RP1, RP2, RP3, RP4, TR1c on the right and left. In this case, the following BRT mode is used: low frequencies (LF) BRT - from 1 to 1000 Hz, with a gain height. A (14-35). In addition to the foot or hand electrodes, plate and point electrodes are connected to the outputs of the device, which are installed on the TA of the pancreas, where deviations from the norm are detected.

In the process of treatment, Voll electropuncture diagnostics of the main biologically active points of the pancreas is performed before and after BRT procedures.

Immediately after the procedure of target therapy, light therapy is carried out with yellow, red and green light in sequence. Use the terminal for light therapy in the apparatus "DETA-Professional". The exposure to light is carried out on the area of the cutaneous projection of the pancreas and on the point TR-1c, and the exposure to each light is carried out for no more than 5 minutes. When exposed to open areas of the skin on the area of the cutaneous projection of the pancreas, a distant technique (0.5-1.5 cm) is used, and light puncture is performed by acting on the TR-1c point using the contact technique using an optical nozzle.

Physical aspects of the colors used:

The wavelength of the emitted yellow light is 590 nm, the light intensity is 3 kJ, the light emission modes are quasi-continuous (1000 or 80 Hz) and modulated (1000 or 80 Hz with modulation = 2 Hz).

The wavelength of the emitted red light is 650 nm, the light intensity is 3-4 kJ, the light emission modes are quasi-continuous (1000 or 80 Hz) and modulated (1000 or 80 Hz with modulation = 2 Hz).

The wavelength of the emitted green light is 520 nm, the light intensity is 4 kJ, the light emission modes are quasi-continuous (1000 or 80 Hz) and modulated (1000 or 80 Hz with modulation = 2 Hz).

Distinctive essential features and a causal relationship between them and the achieved result:

- Parameters of bioresonance exposure at the stage of basic and also targeted therapy, including frequency, gain height, and also temporary exposure.

These parameters are selected as a result of the study.

Bioresonance therapy (BRT) is the treatment of endogenous and exogenous electromagnetic waves of low intensity with a strictly defined shape and frequency with which the body structures resonate. The impact is possible both at the cellular level, the level of membranes, and at the level of the organ, organ system and the whole organism. The main idea of applying resonance in medicine is that with the right selection of the frequency and form of the therapeutic (electromagnetic) effect, it is possible to strengthen normal (physiological) and suppress pathological (disharmonious) fluctuations in the human body. Thus, the bioresonance effect can be directed both to the neutralization of pathological and to the restoration of physiological vibrations disturbed in pathological conditions. The fundamental principle of BRT is the inversion of oscillations taken from the patient’s hand, they arrive at the input of the device, are inverted by 180 °, amplified and fed from the output of the device to the other hand of the patient. In this case, pathological vibrations are damped (eliminated) and destroyed [Galle M: Die MORA-Bioresonanztherapie - einekomplementärmedizinischeMethode. Arzt, Zahnarztund Naturheilverfahren 2007; (1): 7-11].

- Immediately after the targeted therapy, light therapy is carried out with yellow light, red and green light, using the "DETA-Professional" apparatus, using the terminal for light therapy. In this case, the wavelength of the emitted yellow light is 590 nm, the light intensity is 3 kJ, the regimes of yellow light emission are quasi-continuous - 1000 or 80 Hz and modulated - 1000 or 80 Hz with a modulation of 2 Hz; the wavelength of the emitted red light is 650 nm, the light intensity is 3-4 kJ, the modes of red light emission are quasi-continuous - 1000 or 80 Hz and modulated 1000 or 80 Hz with a modulation of 2 Hz; the wavelength of the emitted green light is 520 nm, the light intensity is 4 kJ, the green light emission modes are quasi-continuous - 1000 or 80 Hz and modulated - 1000 or 80 Hz with a modulation of 2 Hz; exposure to light is carried out on the area of the cutaneous projection of the pancreas and on the point TR-1c, with a course of 5-7 procedures, the duration of light therapy is 10-15 minutes.

In the publication "Development Trends, Development and Study of Physiotherapeutic Equipment for Authors Photochromotherapy" A.B. Veselovsky, V.V. Kiryanova, A.S. Mitrofanova, N.N. Petrishcheva, G.D. Fefilova, L.I. Yantareva (ysa.ifmo.ru/data/publications/BOOK003/paper016.pdf) describes the mechanisms of action of various colors of photochromotherapy:

Red radiation is selectively absorbed by molecules of the respiratory chain enzymes (cytochrome oxidase, cytochrome C), the antioxidant system (superoxide dismutase), and reparative regeneration inducers (alkaline phosphatase). Subsequent activation of catabolic processes and stimulation of connective tissue fibroblasts enhance the reparative regeneration of affected tissues. Reducing the impulse activity of nerve conduits of the skin, red radiation leads to a decrease in pain sensitivity in irradiated areas. Acting on biologically active points and zones, it is able to cause reflex reactions of internal organs, segmental connected with irradiated metamers, and stimulate cellular and humoral immunity.

Green radiation is selectively absorbed by flavoproteins of the respiratory chain, protein complexes of calcium ions and is able to change cellular respiration in irradiated tissues. Restoring the activity of the sympatho-adrenal system inhibited by the pathological process, green radiation significantly reduces the intensity of inflammation and autoimmune defects, reduces the heart rate and blood pressure. In addition, green radiation reduces the release of histamine from neutrophils and reduces skin itching.

According to the Swiss company Zepterinternationalcosmetics, light radiation of various colors has the following features of exposure to humans:

- Yellow light strengthens, tones, does not excite, prolongs energy, strengthens too weak processes, strengthens nerves. Yellow light is in effect between red and blue. BLesNouvellesEsthetiques. 1998. No. 1 also noted that yellow light promotes detoxification of the body in all forms.

- Red light activates the energy blocked in the depths, increases dynamism, brings stagnant, inert and reduced processes to a level, exacerbates feelings. Red light in its action is the opposite of blue.

- The green light balances, relaxes, calms, maintains physical and mental energy in dynamic balance, softens tense and painful processes, brings deep peace. Green light is intermediate in its action between blue and yellow.

The degenerative process in the pancreas with type 2 diabetes is manifested by a different degree of burden. During bioresonance, as well as subsequent sequential exposure immediately after it, with three light spectra (yellow, green and red), pancreatic cell regeneration mechanisms are activated and impulse transmission between cells via biophoton communication is improved, which leads to improved insulin secretion by pancreatic cells.

The available literature does not contain information on the treatment of patients with type 2 diabetes mellitus by bioresonance exposure, followed by exposure to sequential light radiation - yellow, green and red.

A total of 150 patients were examined. Patients were divided into 3 groups: in the first group, consisting of 50 people, the claimed method of treatment was tested. The second group also consisted of 50 people and received treatment according to one of the analogue methods (BRT). The third group (placebo), consisting of 50 people, received medication, as well as imaged BRT procedures and color therapy, i.e. treatment with BRT and color therapy was not carried out. The change in the level of analyzed data is presented in Table 1 - Comparative assessment of glycemia, glycated hemoglobin (Hba1c), changes in body weight and quality of life index (sf-36) in 3 groups of patients before and 6 months after treatment (Appendix).

As can be seen from the data presented in the table, the effectiveness of treatment in group 1 is much higher compared to the 2nd and 3rd groups.

The level of glycated hemoglobin in group 3 decreased by 23.2%, while in group 2 the decrease from the initial level was 28.4%. In patients in the 1st group, the level of glycated hemoglobin improved by 38.1%, which is significantly better than in the other groups.

The body mass index in the 1st group decreased by 13.8%, in the 2nd group by 11.2% and in the 3rd group by 7.3%, which confirms the effectiveness of therapy according to the claimed method.

The improvement in the quality of life index (sf-36) in the 1st group was 75.4%, in the 2nd group 52.5% and the 3rd in the group 42.7%, which indicates a significant improvement in the condition of patients in the 1st oh group.

Differences in the reduction of fasting blood sugar were significant - 50.8% (group 1), 44.4% (group 2) and 39.21% (group 3), indicating a significant improvement in group 1.

The reduction in postprandial glycemia in group 1 was 47.01%, in group 2 37.7% and group 3 32.03%, which indicates the effectiveness of the proposed method in compensating for carbohydrate metabolism.

As can be seen from the data presented in the table, before the start of treatment, all patients had a state of decompensation, according to glycated hemoglobin, fasting and postprandial glycemia significantly exceeded normal values.

Indicators of carbohydrate metabolism improved by the end of the course of treatment in all groups, however, only in the 1st group the positive dynamics of the glycemic profile was significant.

After six months of follow-up, positive changes in carbohydrate metabolism persisted, however, only in the 1st group did glycated hemoglobin decrease to the target values, and in the 2nd and 3rd groups, despite a significant decrease in relation to the period before treatment, the level of Hba1c testified to insufficient compensation of carbohydrate metabolism.

In the claimed method, initially, before treatment, biochemical indicators of fasting glycemia and postprandial glycemia were significantly higher than normal, that is, the condition of the patients was significantly worse compared to the prototype. After the therapy by the claimed method, the value of biochemical indicators, body mass index and quality of life index became much better in group 1 compared with the subjects in the 2nd and 3rd groups.

The course of treatment according to the method chosen by us as a prototype is at least 30 days. According to the claimed method is 8-12 days. We consider it necessary to note that out of 50 patients, 10 patients received 8 procedures, 20 patients underwent 10 procedures and 20 patients received 12 treatment procedures. Thus, the treatment according to the claimed method is reduced by 18-22 days, compared with the prototype method.

In a single clinical example for a method for the treatment of type 2 diabetes mellitus (DM) in the description of the patent No. 2463089 it is indicated that the patient underwent 14 procedures followed by drug withdrawal. Further procedures, as indicated in the clinical example, contributed to the maintenance of blood glucose of not more than 6.0 mmol / L. "Before treatment in this patient, the blood glucose in the morning on an empty stomach was 11.0 mmol / L.

In our method of treating type 2 diabetes after a course of treatment (8-12 procedures), the blood glucose in the morning on an empty stomach was also 6.0 mmol / L or less. In the first clinical example of our description, it is indicated that before treatment, the blood glucose in the patient’s morning on an empty stomach was 9.0 mmol / L, and after treatment, 6.0 mmol / L. In the second example, respectively, 8.8 mmol / L and 5.7 mmol / L. In the third example, the fasting glucose level in the patient was 12 mmol / L, and after treatment - 6.0 mmol / L.

Thus, in the inventive method, the glucose content in the blood of patients decreases at an earlier stage of treatment than in the prototype method.

In the prototype method there is no data on the number of patients and there is no information on the glucose content in the blood of patients in the distant period, that is, for example, 6 months after treatment. As we indicated above, after six months of observation, positive changes in carbohydrate metabolism persisted, but only in the 1st group (the claimed method) glycated hemoglobin decreased to target values. 6 months after treatment by the present method, the level of glycated hemoglobin improved by 38.1% (decreased to target values), the body mass index decreased by 13.8%, the improvement in the quality of life index (sf-36) was 75.4%, the decrease in fasting blood sugar was significant - 50.8%, the rate of decrease in postprandial glycemia was 47.01%, which indicates the preservation of a stable treatment result in the long-term period (Table 1).

Thus, the set of essential distinguishing features is new and allows, in comparison with the prototype, to reduce the treatment time for patients with type 2 diabetes mellitus, to reduce the glucose content in the blood of patients at an earlier stage of treatment, as well as to maintain a stable treatment result in the long term.

We give examples of clinical testing of the proposed method for the treatment of patients with type 2 diabetes:

Example 1. Patient M., 47 years old.

Dz: non-insulin-dependent diabetes mellitus with multiple complications, chronic cholecystic pancreatitis, hypertension, osteochondrosis of the spine, polyarthritis of the joints of the lower extremities.

She complained of pain in the abdomen of a aching nature, dry mouth, weakness, lethargy, drowsiness, irritability, fatigue, bloating.

From the anamnesis: Diabetes mellitus was diagnosed during the year, adheres to a diet, takes Metformin orally at a dosage of 1500 mg / day. Physiotherapeutic treatment for this disease has not been previously.

Objectively: Height 168 cm, weight 80 kg. The skin is pale, dry. In the lungs, vesicular breathing, single dry rales. Heart sounds are clear, rhythmic, heart rate 80 in 1 min, blood pressure 160/90 mm Hg The abdomen is soft, slightly painful in the epigastric region upon palpation. Liver at the edge of the costal arch. The spleen is not enlarged.

Pasternatsky’s symptom is negative on both sides. Consciousness is clear, oriented, contact. Body temperature 36.5 ° C.

Clinical and laboratory indicators:

Complete blood count: erythrocytes 4.1, hemoglobin 146, white blood cells 6.0, stab 4, segmented 50, eosinophils 5, lymphocytes 31, monocytes 4, ROE 12.

Urinalysis: slight ketonuria detected.

Fasting glucose test: 9.0 mmol / L.

2 hours after a meal: 13 mmol / L.

Glycated hemoglobin (Hba1c :) 10.1%.

Body mass index: 28.36.

Quality of Life Index: 34.04.

An ultrasound examination of the pancreas revealed diffuse enlargement of the gland and calcifications in the area of the pancreatic head.

ECG: sinus tachycardia, left ventricular hypertrophy and partial blockade of the left bundle branch branch. FLH: within normal limits. Inspection of a gynecologist - pathology not found.

12 daily procedures were carried out using the apparatus "Deta Professional" of the claimed method of treatment, including 2 stages: the stage of basic therapy and the target with subsequent light therapy. 5 basic therapy procedures and 7 target therapy were carried out, and immediately after the targeted therapy procedure, light therapy was performed on the same day. At the stage of basic therapy, a segmental effect was performed on the whole body (using point and plate electrodes: input power 1.5 W, output power 0.7 W, electromagnetic frequency in the low-frequency range 1000 Hz, with an exposure time interval of 30 minutes. Then a bioresonance exposure of the pancreas to the right and left on the acupuncture points (Rp1, Rp2, Rp3, Rp4 TR-1c) Immediately after the BRT procedures, light therapy was performed with yellow light, red and green using the DETA-Professional apparatus, using the term Light exposure was performed on the skin projection area and on the TR-1 point with a course of 7 procedures, a temporary exposure of 15 minutes, the wavelength of the emitted yellow light, 590 nm, the light intensity of 3 kJ, the light emission modes were quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz, the wavelength of the emitted red light, 650 nm, the light intensity of 3-4 kJ, the modes of light emission quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz. The wavelength of the emitted green light, 520 nm, the light intensity is 4 kJ, the modes of light emission are quasi-continuous 80 Hz) and modulated 80 Hz with modulation = 2 Hz).

After treatment, the patient's condition improved significantly: weakness, fatigue, irritability decreased, digestion improved, and abdominal pains decreased. The patient also noted an improvement in overall health. Objectively: the stomach is painless, soft.

After treatment:

Fasting blood glucose test: 6.0 mmol / L.

2 hours after a meal: 7.5 mmol / L.

On an ultrasound examination, the size of the pancreas slightly decreased, the contours are even and uniform in structure.

After treatment after 6 months:

General urine test: revealed the absence of ketonuria.

Fasting glucose test: 5.4 mmol / L.

2 hours after a meal: 7.1 mmol / L.

General urine test: revealed the absence of ketonuria.

Glycated hemoglobin (Hba1c): 6.2%.

Body mass index: 25.65.

Weight reduction of 11 kg.

Quality of Life Index: 60.34.

Example 2. Patient I. 54 years.

Diagnosis: non-insulin-dependent diabetes mellitus with multiple complications, chronic pancreatitis.

He complained of bloating, dry mouth, irritability, dry skin, brittle hair, weakness, increased thirst. From the anamnesis: he has been ill with pancreatitis for 5 years, diabetes was revealed one year ago.

It is monitored by an endocrinologist about diabetes, receives the entire algorithm for the treatment of type 2 diabetes, including metformin, at a dose of 1500-2000 mg / day. Physiotherapeutic treatment for this disease has not been previously.

Objectively: the physique is correct. Adequate nutrition. Height 169 cm, weight 81 kg. The skin is pale, the skin on the elbows is dry. In the lungs, vesicular breathing, no wheezing. Heart sounds are clear, rhythmic, heart rate of 75 in 1 min, blood pressure 140/80 mm Hg The abdomen is soft, slightly painful upon palpation in the area of the projection of the pancreas. Liver at the edge of the costal arch. The spleen is not enlarged. Pasternatsky’s symptom is negative on both sides. Consciousness is clear, oriented, contact, hyperkeratosis of the skin of both feet is determined. Body temperature 36.6 ° C.

Clinical and laboratory indicators:

Complete blood count: red blood cells 4.4, hemoglobin 142, white blood cells 5.0, stab 3, segmented 46, eosinophils 3, lymphocytes 37, monocytes 6, ROE 5.

Urinalysis: minor ketonuria.

Fasting blood glucose test: 8.8 mmol / L.

2 hours after a meal: 12.6 mmol / L.

Glycated hemoglobin: (Hba1c) 10.5%.

Body mass index: 28.42.

Quality of Life Index: 31.35.

An ultrasound examination of the pancreas revealed diffuse enlargement of the gland and polycystic pancreas.

ECG: sinus rhythm, left ventricular hypertrophy. FLH: within normal limits.

12 daily procedures were carried out using the apparatus "Deta Professional" of the claimed method of treatment, including 2 stages: the stage of basic therapy and the target with subsequent light therapy. 5 basic therapy procedures and 7 target therapy were carried out, and immediately after the targeted therapy procedure, light therapy was performed on the same day. At the stage of basic therapy, a segmental effect was performed on the whole body using point and plate electrodes: input power 1.5 W, output power 0.7 W, electromagnetic frequency in the low frequency range 1000 Hz, with an exposure time interval of 30 minutes. Then a bioresonance effect was performed on the acupuncture points (Rp1, Rp2, Rp3, Rp4, TR-1c) of the pancreas on the right and left. Immediately after the BRT procedures, light therapy was carried out with yellow light, red and green using the DETA-Professional apparatus, using the terminal for light therapy. The exposure to light was carried out on the area of the cutaneous projection and on the point TR-1c with a course of 7 procedures, a temporary exposure of 15 minutes. The wavelength of the emitted yellow light is 590 nm, the light intensity is 3 kJ, the modes of light emission are quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz). The wavelength of the emitted red light, 650 nm, the light intensity is 3-4 kJ, the light emission modes are quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz). The wavelength of the emitted green light, 520 nm, the light intensity is 4 kJ, the modes of light emission are quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz).

After BRT therapy, the condition improved significantly: dry mouth, weakness, fatigue, irritability, and digestion improved. The patient notes an improvement in overall health.

Objectively: the stomach is painless soft.

After treatment:

fasting glucose test: 5.7 mmol / L.

2 hours after a meal: 7.2 mmol / L.

On an ultrasound examination, the size of the pancreas slightly decreased, the contours are even and homogeneous, the cysts are preserved, but smaller.

After treatment after 6 months:

General urine test: revealed the absence of ketonuria.

Fasting glucose test: 5.7 mmol / L.

2 hours after a meal: 7.7 mmol / L.

General urine test: revealed the absence of ketonuria.

Glycated hemoglobin (Hba1c): 6.4%.

Body Mass Index: 26.21. Weight loss of 11.2 kg.

Quality of Life Index: 61.25

Example 3. Patient K., 55 years old.

Dz: non-insulin-dependent diabetes mellitus with multiple complications, distal diabetic sensory neuropathy of the lower extremities, IHD, hypertension 2 tbsp., Polyarthritis of the joints of the lower extremities.

She complained of severe thirst, dry mouth, general weakness, pain and numbness of the feet, lethargy, drowsiness, irritability, bloating.

From the anamnesis: Diabetes mellitus was detected in 2010, follows a diet, takes Metformin orally at a dosage of 2000 mg / day. Physiotherapeutic treatment for this disease has not been previously.

Objectively: Height 165 cm, weight 95 kg. The skin is pale, dry. Respiratory rate 16 per minute, vesicular breathing. Heart sounds are clear, rhythmic, heart rate of 78 in 1 min, blood pressure 150/90 mm Hg The abdomen is soft, slightly painful in the epigastric region upon palpation. The liver is enlarged and palpated at the edge of the costal arch. The spleen is not enlarged. Pasternatsky’s symptom is negative on both sides. Consciousness is clear, oriented, contact. Body temperature 36.5 ° C. Symmetric sensory neuropathy of the lower extremities was revealed on the neuropathy scale NSS-7

Clinical and laboratory indicators:

General blood test: red blood cells 4.3, hemoglobin 140, white blood cells 5.0, stab 5, segmented 49, eosinophils 6, lymphocytes 30, monocytes 5, ROE 12.

Urinalysis: detected ketonuria 15 mmol / L.

Fasting glucose test: 12 mmol / L.

2 hours after a meal: 16 mmol / L.

Glycated hemoglobin (Hba1c :) 9.8%.

Body Mass Index: 34.92.

Quality of Life Index: 33.25.

An ultrasound revealed an enlargement of the liver and diffuse pancreas.

ECG: sinus tachycardia, left ventricular hypertrophy and signs of myocardial ischemia. FLH: within normal limits.

Inspection of a gynecologist - pathology not found.

12 daily procedures were carried out using the apparatus "Deta Professional" of the claimed method of treatment, including 2 stages: the stage of basic therapy and the target with subsequent light therapy. 5 basic therapy procedures and 7 target therapy were carried out, and immediately after the targeted therapy procedure, light therapy was performed on the same day. At the stage of basic therapy, a segmental effect was performed on the whole organism (using point and plate electrodes: input power 1.5 W, output power 0.7 W, electromagnetic frequency in the low-frequency range 1000 Hz, with an exposure time interval of 30 minutes. Then pancreatic bioresonance effects on the acupuncture points (Rp1, Rp2, Rp3, Rp4 TR-1c) of the pancreas on the right and left. Immediately after these procedures, light, red and green light therapy was carried out using the DETA-Professional apparatus using the term Nal for light therapy, on the skin projection area and on the point TR-1c. The course of treatment is 7 procedures, a temporary exposure of 15 minutes, the wavelength of the emitted yellow light, 590 nm, the light intensity is 3 kJ, the light emission modes are quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz, the wavelength of the emitted red light, 650 nm, the light intensity of 3-4 kJ, the modes of light emission quasi-continuous 80 Hz and modulated 80 Hz with modulation = 2 Hz. The wavelength of the emitted green light, 520 nm, the light intensity is 4 kJ, the modes of light emission are quasi-continuous 80 Hz) and modulated 80 Hz with modulation = 2 Hz).

After treatment, the patient's condition improved significantly: weakness, fatigue, irritability decreased, digestion improved, leg pain decreased. The patient also noted an improvement in overall health.

Objectively: the stomach is painless, soft. Sensitivity in the lower extremities improved and amounted to a NSS-4 score.

After treatment:

Fasting blood glucose test: 6.0 mmol / L.

2 hours after a meal: 7.8 mmol / L.

There were no ketone bodies in the urine.

On an ultrasound examination, the size of the pancreas slightly decreased, the contours are even and uniform in structure.

After treatment after 6 months:

General urine test: revealed the absence of ketonuria.

Fasting glucose test: 5.5 mmol / L.

2 hours after a meal: 7.5 mmol / L.

General urine test: revealed the absence of ketonuria.

Glycated hemoglobin (Hba1c): 6.4%.

Body Mass Index: 29.41.

Weight reduction of 15 kg.

Quality of Life Index: 68.53.

The inventive method allows, in comparison with the prototype, to reduce the treatment time for patients with type 2 diabetes mellitus, to reduce the glucose content in the blood of patients at an earlier stage of treatment, and also to maintain a stable treatment result in the long term.

Claims (1)

A method of treating patients with type 2 diabetes mellitus, including exposure to radiation, characterized in that bioresonance exposure is preliminarily performed using the DETA-Professional apparatus, which is carried out in 2 stages, the first stage being the basic therapy stage, including 3-5 exposure procedures for the whole body, for which, after taking the measurement, the input electrode is connected to the limb of the patient with the highest electromagnetic potential, and the output to the limb with the lowest electromagnetic potential, p In this case, they act with the following parameters: in the first phase they act without a filter (BF), with a gain height (A) of 20 for 3-4 minutes; in the second phase - low frequencies (LF) 1-1000 Hz, with a gain height (A) of 16, lasting 3-4 minutes, in the third phase they are affected by high frequencies (HF) 1000-10000 Hz, with a gain height (A) equal to 12, lasting 3-4 minutes, exposure is carried out daily; the second stage - the stage of targeted therapy, includes 5-7 procedures for 30-40 minutes each, while affecting the entire anatomical region of the pancreas and its acupuncture points RP1, RP2, RP3, RP4, TR-1c on the right and left, use low frequencies (LF) from 1 to 1000 Hz, with a gain height A equal to 14-35; immediately after that they are affected by yellow light emission with a wavelength of 590 nm, a power of 3 kJ, red light emission with a wavelength of 650 nm, a strength of 3-4 kJ and green light emission of a light wavelength of 520 nm, a strength of 4 kJ, while using a quasi-continuous mode radiation with a frequency of 1000 or 80 Hz and modulated 1000 or 80 Hz with a modulation of 2 Hz, each light is exposed for no more than 5 minutes to the area of the cutaneous projection of the pancreas distantly and to the TR-1 point using the DETA-Professional apparatus, using terminal for light therapy, the effects, as in the first stage, carried out daily.